Anti-TPA Tissue Plasminogen Activator antibody (ab14198)

Overview

  • Product nameAnti-TPA Tissue Plasminogen Activator antibody
    See all TPA Tissue Plasminogen Activator primary antibodies
  • Description
    Goat polyclonal to TPA Tissue Plasminogen Activator
  • SpecificityThere were no cross reactivities obtained with human uPA and PAI2.
  • Tested applicationsSuitable for: ELISA, IHC-Fr, IHC-Pmore details
  • Species reactivity
    Reacts with: Rat, Human
  • Immunogen

    Full length native protein (purified) (Human).

Properties

Applications

Our Abpromise guarantee covers the use of ab14198 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent dilution.
IHC-Fr 1/50 - 1/100.
IHC-P 1/50. Pretreatment with 0.05% Pronase E for 20 minutes is recommended.

Target

  • FunctionConverts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.
  • Tissue specificitySynthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
  • Involvement in diseaseNote=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
  • Sequence similaritiesBelongs to the peptidase S1 family.
    Contains 1 EGF-like domain.
    Contains 1 fibronectin type-I domain.
    Contains 2 kringle domains.
    Contains 1 peptidase S1 domain.
  • DomainBoth FN1 and one of the kringle domains are required for binding to fibrin.
    Both FN1 and EGF-like domains are important for binding to LRP1.
    The FN1 domain mediates binding to annexin A2.
    The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.
  • Post-translational
    modifications
    The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.
    Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.
    N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.
    Characterization of O-linked glycan was studied in Bowes melanoma cell line.
  • Cellular localizationSecreted > extracellular space.
  • Information by UniProt
  • Database links
  • Alternative names
    • Alteplase antibody
    • DKFZp686I03148 antibody
    • Plasminogen activator tissue antibody
    • Plasminogen activator tissue type antibody
    • PLAT antibody
    • Reteplase antibody
    • t PA antibody
    • T Plasminogen Activator antibody
    • t-PA antibody
    • T-plasminogen activator antibody
    • Tissue plasminogen activator (t PA) antibody
    • Tissue type plasminogen activator antibody
    • Tissue-type plasminogen activator chain B antibody
    • tPA antibody
    • TPA_HUMAN antibody
    • TPA1 antibody
    see all

Anti-TPA Tissue Plasminogen Activator antibody images

  • a14198 staining TPA Tissue Plasminogen Activator (A - blue) in Rat hippocampal/thalamic region tissue sections by Immunohistochemistry (IHC-Fr - frozen sections). Tissue was fixed with paraformaldehyde. Tissue was incubated in pre-block solution (10% normal hourse serum in antibody diluent (PBS + 0.1% Trition X-100)) for 1 hour. Samples were incubated with primary antibody (1/50 in PBS + pre-block solution) for 16 hours. B - trypsin (red), C - PAR2 (green), D - merge.

    TPA Tissue Plasminogen Actvator and Trypsin co-localise.

  • ab14198 at 1/50 staining rat brain hippocampus pyramidal neuron tissue sections by IHC-Fr. The tissue was blocked with horse serum and incubated for 16 hours with the antibody. An AMCA conjugated donkey antibody was used as the secondary.

    See Abreview

References for Anti-TPA Tissue Plasminogen Activator antibody (ab14198)

This product has been referenced in:
  • Granieri L  et al. A competition-based assay for the screening of species-specific antibiotics. J Antimicrob Chemother 64:62-8 (2009). IF ; Human . Read more (PubMed: 19401303) »
  • Lohman RJ  et al. Protease-activated receptor-2 regulates trypsin expression in the brain and protects against seizures and epileptogenesis. Neurobiol Dis 30:84-93 (2008). IHC-Fr ; Rat . Read more (PubMed: 18313316) »

See all 2 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Frozen sections)
Sample Rat Tissue sections (Brain, Hippocampus, pyramidal neurons)
Specification Brain, Hippocampus, pyramidal neurons
Fixative Paraformaldehyde
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10%
Username

Mr. Rink-Jan Lohman

Verified customer

Submitted May 08 2007

Thank you for your enquiry. I have been in contact with the originator of this antibody and have received the protocol that they used. Immunostraining Formalin-Fixed, Paraffin Embedded Tissues 1. Dewaxing: Xylene 5 min.- Xylene 5 min.- Xylene 5 m...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"